Trading update – January 2015 - Tarsus...Plastimagen EJ Krause relationship working well INDONESIA...

Trading update – January 2015

agenda ■ Operational review

■ Strategic update

■ Outlook

■ Summary

■ Q&A

2

Operational Review

2014 Operational review

■ Good Q4 performance and a successful year - in line with expectations

■ Like for like revenue growth at 10%

■ Currency headwinds for much of the year

■ Major events performed well

■ Good progress made in portfolio development

■ AAITF and Zuchex replications ■ 5 strategic acquisitions

■ Balance sheet position strong

4

2014 Operational review – Emerging Markets TURKEY

■ Good performance overall ■ Large shows – Zuchex, Sign and Flower Show – all

strong

DUBAI ■ GESS and MEBA very strong in both visitor numbers

and revenues

CHINA ■ Hope revenues well up on 2013 ■ SIUF performed well in its first edition and has great

potential ■ AAITF successfully transitioned to Shenzhen for 2015

5

2014 Operational review – Emerging Markets MEXICO

■ Good performances from Expo Manufactura and Plastimagen

■ EJ Krause relationship working well

INDONESIA ■ Construction events performed well ■ Two replications successfully launched ■ Joint venture with DMG established

6

2014 Operational review – USAOFF-PRICE

■ Continued solid growth

■ Venue extended to 2019

MEDICAL ■ Both Orlando and Las Vegas shows had record editions

■ Education revenues below 2013 levels

■ Successful MMI launch central to educational repositioning

■ Cardio performed strongly in its first edition

7

2014 Operational review – europeFRANCE

■ 18% of French business sold to management

■ Trading over the year flat on 2013

3D PRINT ■ Good first events in London and Paris

■ Integration progressing very well

■ Aggressive launch plan for 2015 – on track

8

strong balance sheet ■ Net debt and cash flows in line with expectations

■ Major outflows for acquisitions and deferred consideration

■ Gearing at 1.7x EBITDA (historic 24 months basis)

■ Bank facilities of £60m extended to 2019

9

Strategic update

Differentiating Tarsus ■ Entrepreneurial management culture

■ Markets in transition

■ Geographical footprint - targeting specific markets

■ Quality of assets

11

revenue mix2010/11 2014/15*

Europe USA Emerging Markets (inc JVs)

*Based on market consensus

12

quickening the pace

KPIS 2013 2014 target

ACCELERATING EPS GROWTH* a a 5-10% pa

INCREASING SHARE OF REVENUES FROM EM AND US a a 75%+

DRIVING VISITOR / BUYER GROWTH a a 3%

*on constant currencies

13

2014 Strategic progress

■ Geographical footprint established – growth economies

■ China ■ South East Asia ■ Turkey ■ Dubai ■ Mexico ■ US

■ Replications launched to drive organic growth

■ Zuchex ■ AAITF ■ GESS ■ 3D Print

14

2014 Strategic progress

■ Acquisitions strengthening the portfolio

■ Disposal of 18% French Division

SIUF

Komatek

3D Print Show

The Cardiometabolic Health Congress

The South Beach Symposium

5

15

aaitfkey event themes

electronics – in car

entertainment

car customisation

auto parts equipment

16

Tarsus Medical Division

18

Tarsus Medical Division - History

NOV 2006 ■ Acquisition of MCII – exhibition and conference business with $6m revenue

2010 ■ Launch online educational products

2013 ■ Total revenues $18.3m; 49% shows, 51% education (of which 28% online)

2014 ■ Launched Metabolic Medical Institute (MMI) ■ Acquire Cardiometabolic Health Congress

NOV 2014 ■ Acquired South Beach Symposium for $6.4m, adding dermatology to portfolio.

RevenueCAGR17%

Preventative Medicine – why it is a good market

■ Preventative Medicine market

■ Large and established market in US ■ 900,000 doctors in US

■ Landscape is changing / in transition

■ Obamacare ■ Preventative Medicine moving mainstream ■ Board Certification ■ Prestigious Universities looking to enter market

e.g. Harvard, GWU

19

Medical Division ■ Educational revenues have slowed

■ Emergence of more competitors ■ Saturation of niche Anti Aging market ■ Obamacare ■ Launch into mainstream medicine market

20

strategymoving into mainstream market

cardiovascular

cardio

cancer

south beach symposium

endocrinology

Core product of MMI

neurology

being developed

4 pillars of preventative medicine

21

Medical – 2015 Priorities

■ Integrate SBS into Tarsus Medical

■ Drive organic growth

■ Replications of events e.g. Cardio regional events ■ New education products ■ Increased investment in organic growth ■ Leverage databases acquired with Cardio and

SBS

22

Outlook

2015 Outlook ■ Like for like bookings tracking 10%+

■ Large biennials well ahead of prior editions

■ Medical education business stabilising during 2015

■ AAITF relocation to Shenzhen successful and is performing ahead of expectations

24

Summary ■ 2014 a successful year

■ Good strategic progress

■ Like for like revenue growth at 10%

■ Replications delivered and complementary acquisitions made

■ Well positioned for 2015 with strong forward bookings

■ Given geopolitical environment we remain cautious in our budget for 2015

25

Q & A

Appendix

Macroeconomic assumptions

FX Rates for 2015 GDP Growth rates 2015

US$1.60 UK 2.0%

Euro €1.25 US 3.0%

T Lira 3.65 Turkey 3.5%

RMB 9.80 China 7.0%

IDR 19,500 Indonesia 5.5%

Mexico 3.5%

France 1.0%

28